StockData
CNS Pharmaceuticals, Inc. logo

CNS Pharmaceuticals, Inc. (CNSP) stock

CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$4.44+0.29 (+6.99%)

Close on Nov 18, 2026Market cap $6.49MP/E –Yield –

CNS Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

CNS Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$16.91M. For fiscal 2025 it was -$15.99M. The highest annual figure on record is -$881.79K in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$15.99M–
FY2024Dec 31, 2024-$14.90M–
FY2023Dec 31, 2023-$18.87M–
FY2022Dec 31, 2022-$15.27M–
FY2021Dec 31, 2021-$14.49M–
FY2020Dec 31, 2020-$9.45M–
FY2019Dec 31, 2019-$3.83M–
FY2018Dec 31, 2018-$881.79K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.70M–
Q1 FY2026Mar 31, 2026-$4.98M–
Q4 FY2025Dec 31, 2025-$5.99M–
Q3 FY2025Sep 30, 2025-$3.25M–
Q2 FY2025Jun 30, 2025-$2.41M–
Q1 FY2025Mar 31, 2025-$4.34M–
Q4 FY2024Dec 31, 2024-$3.20M–
Q3 FY2024Sep 30, 2024-$5.63M–
Q2 FY2024Jun 30, 2024-$2.53M–
Q1 FY2024Mar 31, 2024-$3.54M–
Q4 FY2023Dec 31, 2023-$5.38M–
Q3 FY2023Sep 30, 2023-$4.53M–
Q2 FY2023Jun 30, 2023-$4.03M–
Q1 FY2023Mar 31, 2023-$4.93M–
Q4 FY2022Dec 31, 2022-$5.13M–
Q3 FY2022Sep 30, 2022-$3.42M–
Q2 FY2022Jun 30, 2022-$3.56M–
Q1 FY2022Mar 31, 2022-$3.15M–
Q4 FY2021Dec 31, 2021-$3.25M–
Q3 FY2021Sep 30, 2021-$3.81M–
Q2 FY2021Jun 30, 2021-$3.81M–
Q1 FY2021Mar 31, 2021-$3.61M–
Q4 FY2020Dec 31, 2020-$3.00M–
Q3 FY2020Sep 30, 2020-$2.01M–
Q2 FY2020Jun 30, 2020-$2.47M–
Q1 FY2020Mar 31, 2020-$1.97M–
Q4 FY2019Dec 31, 2019-$2.52M–
Q3 FY2019Sep 30, 2019-$699.09K–
Q2 FY2019Jun 30, 2019-$415.06K–
Q1 FY2019Mar 31, 2019-$195.09K–
Q4 FY2018Dec 31, 2018-$208.58K–
Q3 FY2018Sep 30, 2018-$169.91K–

More CNS Pharmaceuticals figures

See a number that looks wrong?